DE602004006118D1 - 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER - Google Patents

2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER

Info

Publication number
DE602004006118D1
DE602004006118D1 DE602004006118T DE602004006118T DE602004006118D1 DE 602004006118 D1 DE602004006118 D1 DE 602004006118D1 DE 602004006118 T DE602004006118 T DE 602004006118T DE 602004006118 T DE602004006118 T DE 602004006118T DE 602004006118 D1 DE602004006118 D1 DE 602004006118D1
Authority
DE
Germany
Prior art keywords
alzheimer
gamma
treatment
acid derivatives
carboxyl acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004006118T
Other languages
English (en)
Other versions
DE602004006118T2 (de
Inventor
Guido Galley
Robert Alan Goodnow
Jens Uwe Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004006118D1 publication Critical patent/DE602004006118D1/de
Application granted granted Critical
Publication of DE602004006118T2 publication Critical patent/DE602004006118T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
DE602004006118T 2003-05-19 2004-05-14 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER Expired - Lifetime DE602004006118T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03011040 2003-05-19
EP03011040 2003-05-19
PCT/EP2004/005177 WO2004100958A1 (en) 2003-05-19 2004-05-14 2, 3, 4, 5-tetrahydrobenzo[f][1, 4]oxazepine-5-carboxylic acid amide derivatives as gamma-secretase inhibitors for the treatment of alzheimer’s disease

Publications (2)

Publication Number Publication Date
DE602004006118D1 true DE602004006118D1 (de) 2007-06-06
DE602004006118T2 DE602004006118T2 (de) 2008-01-03

Family

ID=33442730

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006118T Expired - Lifetime DE602004006118T2 (de) 2003-05-19 2004-05-14 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER

Country Status (19)

Country Link
US (1) US7060698B2 (de)
EP (1) EP1631296B1 (de)
JP (1) JP4510021B2 (de)
KR (1) KR100731368B1 (de)
CN (1) CN1794997B (de)
AR (1) AR044363A1 (de)
AT (1) ATE360424T1 (de)
AU (1) AU2004238037B2 (de)
BR (1) BRPI0410647A (de)
CA (1) CA2524640C (de)
CL (1) CL2004001068A1 (de)
DE (1) DE602004006118T2 (de)
ES (1) ES2285458T3 (de)
MX (1) MXPA05012368A (de)
MY (1) MY143953A (de)
PL (1) PL1631296T3 (de)
RU (1) RU2332408C2 (de)
TW (1) TWI290550B (de)
WO (1) WO2004100958A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200502221A (en) 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
CN101115730A (zh) * 2004-12-14 2008-01-30 阿斯利康(瑞典)有限公司 新分子探针
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8855099B2 (en) 2007-03-19 2014-10-07 Qualcomm Incorporated Selective phase connection establishment
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
JP5275315B2 (ja) * 2010-10-01 2013-08-28 学校法人近畿大学 新規化合物及びβ−セクレターゼ阻害剤
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
NO3175985T3 (de) 2011-07-01 2018-04-28
US11649218B2 (en) 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
PT944645E (pt) * 1996-12-06 2005-06-30 Vertex Pharma Inibidores da enzima conversora de interleucina 1beta
CA2413429A1 (en) 2000-06-23 2001-12-27 Takeda Chemical Industries, Ltd. Benzoxazepinones and their use as squalene synthase inhibitors
JP2002080468A (ja) * 2000-06-23 2002-03-19 Takeda Chem Ind Ltd ベンゾオキサゼピン化合物
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
US7060798B2 (en) * 2002-05-13 2006-06-13 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Modified protein adhesives and lignocellulosic composites made from the adhesives
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives

Also Published As

Publication number Publication date
TW200510355A (en) 2005-03-16
TWI290550B (en) 2007-12-01
WO2004100958A1 (en) 2004-11-25
DE602004006118T2 (de) 2008-01-03
CN1794997A (zh) 2006-06-28
CN1794997B (zh) 2010-05-12
AR044363A1 (es) 2005-09-07
RU2005139529A (ru) 2006-08-10
KR20060003107A (ko) 2006-01-09
US20040235819A1 (en) 2004-11-25
JP4510021B2 (ja) 2010-07-21
MY143953A (en) 2011-07-29
ES2285458T3 (es) 2007-11-16
CA2524640C (en) 2011-10-11
MXPA05012368A (es) 2006-02-02
CA2524640A1 (en) 2004-11-25
US7060698B2 (en) 2006-06-13
EP1631296A1 (de) 2006-03-08
PL1631296T3 (pl) 2007-08-31
AU2004238037A1 (en) 2004-11-25
EP1631296B1 (de) 2007-04-25
AU2004238037B2 (en) 2009-11-26
ATE360424T1 (de) 2007-05-15
CL2004001068A1 (es) 2005-04-15
KR100731368B1 (ko) 2007-06-21
RU2332408C2 (ru) 2008-08-27
BRPI0410647A (pt) 2006-07-04
JP2007501261A (ja) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE368031T1 (de) Neue gamma secretase inhibitoren
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP1643986A4 (de) Phenylcarboxylat-beta-secretase-hemmer zur behandlung von morbus alzheimer
EP1756040A4 (de) Als -sekretaseinhibitoren zur behandlung von alzheimer-krankheit geeignete phenylcarbonsäureamidverbindungen
EP1951709A4 (de) Imidazolidinon-verbindungen als beta-secretase-hemmer zur behandlung von alzheimer
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE439347T1 (de) 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
ATE345340T1 (de) N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition